Drugs / CT125B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05487495 | Aug 2022 → Dec 2023 | T lymphoblastic leukemia/lymphoma | Beijing Boren Hospital | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT125B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05487495 ↗ |
| Modality | Cell therapy | “CAR T cells” NCT05487495 ↗ |
| Target | CD5 | “CD5 CAR T (CT125B)” NCT05487495 ↗ |